Allphase Pharma Consulting, LLC
A Professional Service Provider for the Pharma Industry
This December, Achaogen released much data on 2 plazomicin trials[1]: the pivotal EPIC study comparing plazomicin / levofloxacin with meropenem / levofloxacin in cUTI is the one we want to look at today because it is interpretable, while the other trial Continue reading All Smiles at the Press Conference: Plazo+Levo Delivers
After the first 100 blogs, it is appropriate to reflect on reader preferences. When I arbitrarily select a topic, it is not always clear whether what interests me also interests you. Since its start 1½ years ago, this blog has grown Continue reading ALLPHASE PHARMA – THE FIRST 100 BLOG POSTS
>>> For the latest QIDP list, please click HERE <<< Since our last QIDP blog from April 8, 2015, several new drugs have made the list which now includes 41 compounds. Below a table which includes compound, sponsor and development stage (Phase). It Continue reading QIDP Drugs – 4th Edition
Since the publication of a series of posters at ICAAC 2014, we finally know what’s hidden behind the ‘Carbavance’ name. ‘Carbavance’ stands for the combination of meropenem with the B-lactamase inhibitor RPX7009 which The Medicines Company (TMC) inlicensed from Rempex Continue reading What’s in a Name? Would ‘Carbavance’ Still Smell as Sweet?
Why are there so few boron-containing drugs on the market? The cancer drug bortezumib (Velcade®) may be the only better-known drug on the market with a boron atom in its structure.[1] Among antibiotics, there is Kerydin™ (tavaborole), an approved topical Continue reading Not So Boring: Boron-Containing Antibiotics Create a Stir